Included Health vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Included Health provides comprehensive health navigation and care delivery for employers, specializing in complex conditions, mental health, and LGBTQ+ healthcare needs.
About
Included Health is a digital health company formed through the 2021 merger of Grand Rounds Health and Doctor On Demand, creating a unified platform for health navigation and virtual care delivery for employer health plans. The company provides members with access to expert second opinions, specialist referrals, primary care, mental health services, and benefits navigation through a single integrated platform. Included Health has built specialized expertise in serving populations with complex care needs including members with serious diagnoses, those seeking LGBTQ+-affirming care, and employees navigating mental health challenges. The company raised over $300M and serves large self-insured employers as a comprehensive health benefit that supplements traditional insurance. The merger combined Grand Rounds' navigation and expert medical opinion capabilities with Doctor On Demand's virtual primary care and psychiatry platform, creating broader clinical coverage than either company offered independently. Included Health positions itself as a health equity platform that improves outcomes for all employees regardless of their health complexity, geographic location, or demographic characteristics.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.